Cargando…
Combined therapy with adipose tissue-derived mesenchymal stromal cells and meglumine antimoniate controls lesion development and parasite load in murine cutaneous leishmaniasis caused by Leishmania amazonensis
BACKGROUND: Leishmaniasis is a neglected disease caused by Leishmania spp. One of its characteristics is an imbalance of host immune responses to foster parasite survival. In this setting, mesenchymal stromal cells (MSCs) may be a viable therapeutic alternative, given their well-established immunomo...
Autores principales: | Ramos, Tadeu Diniz, Silva, Johnatas Dutra, da Fonseca-Martins, Alessandra Marcia, da Silveira Pratti, Juliana Elena, Firmino-Cruz, Luan, Maciel-Oliveira, Diogo, Dos-Santos, Julio Souza, Tenorio, João Ivo Nunes, de Araujo, Almair Ferreira, Freire-de-Lima, Célio Geraldo, Diaz, Bruno Lourenço, Cruz, Fernanda Ferreira, Rocco, Patricia Rieken Macedo, de Matos Guedes, Herbert Leonel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457509/ https://www.ncbi.nlm.nih.gov/pubmed/32867857 http://dx.doi.org/10.1186/s13287-020-01889-z |
Ejemplares similares
-
AgNP-PVP-meglumine antimoniate nanocomposite reduces Leishmania amazonensis infection in macrophages
por: Gélvez, Ana Patricia Cacua, et al.
Publicado: (2021) -
Pharmacokinetics of neutron-irradiated meglumine antimoniate in
Leishmania amazonensis-infected BALB/c mice
por: Borborema, Samanta Etel Treiger, et al.
Publicado: (2019) -
Effects of Bone Marrow Mesenchymal Stromal Cell Therapy in Experimental Cutaneous Leishmaniasis in BALB/c Mice Induced by Leishmania amazonensis
por: Pereira, Joyce Carvalho, et al.
Publicado: (2017) -
FIRST REPORT ON OTOTOXICITY OF MEGLUMINE
ANTIMONIATE
por: Valete-Rosalino, Cláudia Maria, et al.
Publicado: (2014) -
The role of TLR9 on Leishmania amazonensis infection and its influence on intranasal LaAg vaccine efficacy
por: Pratti, Juliana Elena Silveira, et al.
Publicado: (2019)